Author: Ken Dropiewski

Colibri’s transcatheter aortic valve [TAVR] EU pilot study validates its pre-mounted, pre-packaged, dry tissue, ready-to-use balloon-expanded valve with demonstration of superior hemodynamics

LOUISVILLE, Colo., Dec. 1, 2023 /PRNewswire/ — The initial findings of Colibri Heart Valve’s multicenter high-risk TAVR EU pilot study were presented at PCR London Valves November 20th, 2023. The study was conducted by CERC (Centre Européen de Recherche Cardiovasculaire) as acting CRO (clinical research organization).
Speaking on behalf of the study’s team of investigators, Dr Bernard Chevalier, principal investigator, L’hôpital Privé Jacques Cartier, Massy, France, presented the primary 30-day endpoint results of the trial in the 26 patients, classified at high-risk for surgical aortic valve replacement, who received the Colibri dry tissue TAVR valve utilizing the pre-mounted, pre-packaged delivery system. All patients survived to the initial 30-day milestone. Central core laboratory measurements indicated notably high measures of hemodynamic valve performance, including mean valve area of 2.23 cm2 and mean Doppler index of 0.56 at 30 days.
The report represents major clinical validation of Colibri’s ground-breaking, world’s first TAVR system utilizing a pre-mounted, pre-packaged, dry tissue, ready-to-use balloon-expanded valve and system design that does not involve mounting of the valve prosthesis in the catheterization laboratory. The hemodynamic performance of Colibri’s unique, innovative leaflet design appears to surpass that of predicate balloon-expanded TAVR valves.
Professor David Hildick-Smith, Head of Structural Heart Disease at the University Hospitals Sussex in Brighton, UK, said “The Colibri pre-mounted TAVI system is very straightforward and efficient. It comes preloaded in its packaging – just like a coronary stent does. We can take the system directly from its packaging and implant it in the patient. There is no need for valve crimping, loading, or other technical assistance. Furthermore, and crucially, the valve area obtained is significantly greater than with other valve systems, and this may prove very advantageous in terms of symptom resolution and valve durability.”
Colibri believes these results provide strong validation of its innovative pre-mounted TAVR valve—the first truly ready-to-use valve system that will set a new standard in structural heart technology, and the company now looks forward to launching its FDA feasibility trials.
About Colibri Heart Valve:
Colibri Heart Valve LLC (“Colibri”) is a privately held medical device company that researches and develops novel, patent protected, structural heart technologies. Colibri was formed in 2010 and through its proprietary tissue technology and valve design, Colibri has developed a pre-mounted, pre-crimped, and pre-loaded, Ready-for-Use balloon expandable transcatheter aortic valve implantation (TAVI) system called the “Colibri TAVI System.” The Colibri technology is protected by both trade secrets and issued and pending patent applications with priority claims and content dating back to January 4, 2002.
For more information please contact:
Thomas Wolf 303-808-2570.
SOURCE Colibri Heart Valve

Silence Therapeutics Strengthens Executive Leadership Team with Key Appointments

LONDON–(BUSINESS WIRE)–Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced Curtis Rambaran, MD, previously Silence’s Vice President, Head of Clinical Science, has been promoted to Chief Medical Officer, and Marie […]

Johnson & Johnson MedTech Acquires Laminar, Inc.

NEW BRUNSWICK, N.J.–(BUSINESS WIRE)–Johnson & Johnson MedTech1 today announced the completion of the acquisition2 of Laminar, Inc., a privately-held medical device company focused on eliminating the left atrial appendage (LAA) in patients with non-valvular atrial fibrillation (AFib). Johnson & Johnson MedTech acquired Laminar for an upfront payment of $400 million, subject to […]

Cyclerion Strengthens Board of Directors with Experienced Company Builder and Cutting-edge Innovator

– Dina Katabi, Ph.D.: World leader in healthcare AI applications at MIT; inventor of groundbreaking wireless devices for passive assessment of symptoms, behavior, and treatment responses in neurological and psychiatric disorders – Michael Higgins: Seasoned biopharma executive possessing business and financial acumen with CEO and extensive board experience; former entrepreneur-in-residence […]

Avricore Health Corporate Update – Company Demonstrates Strong Growth

VANCOUVER, British Columbia, Nov. 30, 2023 (GLOBE NEWSWIRE) — AVRICORE HEALTH INC. (TSXV: AVCR) (the “Company” or “AVCR”) reports on its third quarter results which demonstrate significant growth in pharmacy locations offering HealthTab driving strong revenue growth and operational cashflow positivity. With demand for clinical services growing in pharmacies thanks […]

Procyrion Announces First Patient Enrollments in the DRAIN-HF Pivotal IDE Trial for Aortix™ Percutaneous Mechanical Circulatory Support Technology

Technology to be evaluated in acute decompensated heart failure patients, where current treatment options remain ineffective and lacking HOUSTON, Nov. 30, 2023 /PRNewswire/ — Procyrion, Inc., a medical device company dedicated to improving outcomes for patients with cardiac and renal…

ReValve Solutions Announces Successful First-in-Human Trial with Next-Generation Technology for Transcatheter Mitral Valve Replacement

IRVINE, California–(BUSINESS WIRE)–ReValve Solutions Inc. (ReValve), que ha desarrollado una tecnología de nueva generación para facilitar el reemplazo transcatéter de la válvula mitral, dio a conocer que un hombre de 81 años, con antecedentes de insuficiencia cardiaca, una serie de injertos quirúrgicos de by-pass fallidos y regurgitación de la válvula mitral grave (RM 4+), fue tratado con éxito con el sistema de Palmetto. El procedimiento de reemplazo transcatéter de la válvula mitral de últ